The Readout

By  Damian Garde

Your guide to what’s new in biotech. Sign up for the newsletter here.

The READOUT
The Readout

A debatable drug price & the possible end of Theranos

By Damian Garde

The READOUT
The Readout

Using CRISPR for chemo & an updated biotech scorecard

By Damian Garde

The READOUT
The Readout

Celgene’s Tesla potential & biotech at the movies once more

By Damian Garde

The READOUT
The Readout

A painful biotech lesson & a ‘wake-up’ call for researchers

By Damian Garde

The READOUT
The Readout

Spark’s gene therapy future & a new idea in Medicare

By Damian Garde

The READOUT
The Readout

Alnylam’s long-awaited milestone & Teva’s problem with migraines

By Damian Garde

The READOUT
The Readout

China’s llama-esque CAR-T & digitizing clinical trials

By Damian Garde

The READOUT
The Readout

Life without PBMs & an award for ‘hated’ pharma CEOs

By Damian Garde

The READOUT
The Readout

A biotech milestone in Hong Kong & Regeneron’s rebound

By Damian Garde

The READOUT
The Readout

Akcea’s FDA countdown & Pfizer’s vision of the future

By Damian Garde

The READOUT
The Readout

Biotech’s hottest job title & Hong Kong’s IPO waters

By Damian Garde

The READOUT
The Readout

Gottlieb’s trial plan & a new Gilead CEO

By Damian Garde

The READOUT
The Readout

Gilead’s gilded age & Biogen’s ‘positive’ negativity

By Damian Garde

The READOUT
The Readout

Unprecedented Alzheimer’s data & a landing pad at Google

By Damian Garde

AbbVie California
The Readout

AbbVie’s debatable blockbuster & Biogen’s day of reckoning

By Damian Garde

The Readout

Wall Street’s appetite for biotech risk & Biogen’s sliding doors

By Damian Garde

The READOUT
The Readout

Awaiting Biogen on Alzheimer’s & Trump’s pricing plan takes shape

By Damian Garde

The READOUT
The Readout

Your guide to earnings & a pharma nightmare comes true

By Damian Garde

The READOUT
The Readout

Wall Street loves preclinical biotech & Amarin’s hour is at hand

By Damian Garde

The READOUT
The Readout

Daraprim sales are falling & nobody’s buying private biotechs

By Damian Garde

The READOUT
The Readout

CAR-T’s logistical hurdle & PhRMA’s idea for cutting out middlemen

By Damian Garde

The READOUT
The Readout

Craig Venter’s HLI successor & Daraprim 2.0

By Damian Garde

The READOUT
The Readout

Biogen’s debatable future & Zogenix’s FDA memory-jog

By Damian Garde

The READOUT
The Readout

A new CRISPR trick & career advice for academics

By Damian Garde

The READOUT
The Readout

Celgene on a roll & the downside of transparency

By Damian Garde

The READOUT
The Readout

Biotech’s pipeline creativity & Grail’s turnover

By Damian Garde

The READOUT
The Readout

Tackling TCRs & Anavex’s blazing red flags

By Damian Garde

The READOUT
The Readout

Biotech’s six months of surprises & Sarepta’s long game

By Damian Garde

The READOUT
The Readout

Dogged drug price increases & Hong Kong’s biotech future

By Damian Garde

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy